TSBX Overview

Investigation into Company Sales: Halper Sadeh LLC is investigating GMS Inc., Turnstone Biologics Corp., and Big 5 Sporting Goods Corp. for potential violations of federal securities laws related to their recent sales, seeking increased consideration and disclosures for shareholders.

Legal Assistance Offered: The firm encourages affected shareholders to contact them for free legal consultations regarding their rights and options, operating on a contingent fee basis with no upfront costs for clients.

Class Action Firm Recognition: Monteverde & Associates PC, led by attorney Juan Monteverde, is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has successfully recovered millions for shareholders.

Investigation into Turnstone Biologics: The firm is investigating the sale of Turnstone Biologics Corp. to XOMA Royalty Corporation, where existing shareholders will receive $0.34 per share and a contingent value right, raising questions about the fairness of the deal.

Merger Agreement: XOMA Royalty Corporation has entered into a definitive agreement to acquire Turnstone Biologics Corp. for $0.34 per share in cash, along with a contingent value right (CVR) that has undisclosed terms, following approval from Turnstone's board.

Transaction Details: The acquisition includes a tender offer expected by July 11, 2025, and aims to close in August 2025, pending conditions such as majority shareholder support, with 25.2% of Turnstone shareholders already agreeing to the deal.

Investigation of Companies: Halper Sadeh LLC is investigating MRC Global Inc. and Turnstone Biologics Corp. for potential violations related to their sales to DNOW Inc. and XOMA Royalty Corporation, respectively, and is offering legal assistance to affected shareholders.

Legal Rights and Options: Shareholders of MRC, Turnstone, and DNOW are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options regarding the proposed transactions, with the firm operating on a contingent fee basis.

Merger Announcement: XOMA Royalty Corporation has entered into a definitive merger agreement to acquire Turnstone Biologics Corp. for $0.34 in cash per share, along with a non-transferable contingent value right (CVR), with the transaction expected to close in August 2025.

Board Approval and Support: The Turnstone Board of Directors unanimously approved the acquisition, and approximately 25.2% of Turnstone stockholders have signed agreements to support the merger by tendering their shares.

Merger Announcement: XOMA Royalty has agreed to acquire Turnstone Biologics for $0.34 per share in cash, along with a contingent value right (CVR), with the deal supported by investors holding nearly 25% of Turnstone's stock.

Tender Offer Details: The acquisition will involve a tender offer for all outstanding shares of Turnstone, and upon closing, remaining shares will convert into rights for the same cash consideration and CVR.